Bank of America
AAPG

Bank of America’s Ascentage Pharma AAPG Stock Holding History

Bank of America’s Portfolio AAPG Stock Details AAPG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-201
Closed -$5.27K – 7147
2025
Q4 		$5.27K Buy
201
+21
+12% +$687 ﹤0.01% 6266
2025
Q3 		$7.03K Buy
+180
New +$7.29K ﹤0.01% 7259

Other funds holding AAPG

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
XC
XY Capital Central, Hong Kong $101M AUM 1.14% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

Bank of America's AAPG Position: Q1 2026 in Review

Bank of America sold out of Ascentage Pharma (AAPG) in Q1 2026, closing a stake of 201 shares — an estimated $5.27K sold.

Bank of America first reported a position in AAPG in Q3 2025 and held it in 2 quarters. The position peaked at $7.03K in Q3 2025. 7 funds tracked by Wall St. Rank hold AAPG as of Q1 2026.

  • Bank of America reported no remaining Ascentage Pharma position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 201 Ascentage Pharma shares in Q1 2026, an estimated $5.27K.
  • Bank of America first reported a position in Ascentage Pharma in Q3 2025 and held it in 2 quarters.
  • Bank of America's Ascentage Pharma position peaked at $7.03K in Q3 2025.
  • 7 funds tracked by Wall St. Rank held Ascentage Pharma as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.